Clinical Trial

Effects of Vivatlac Synbiotic on Gut Micribiota of IBS Patients

Study acronym: ViIBS3
Recruiting
View on ClinicalTrials.gov →
Summary
Multi-center, randomized, double-blind, placebo-controlled, 12 weeks trial investigating the effects of a nine-strain synbiotic (Vivatlac Synbiotikum) on the gut microbiota of IBS patients
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-14.
Status change: Not Yet Recruiting → Recruiting 2025-12-09
Trial Details
NCT Number NCT07235228
Lead Sponsor The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz
Conditions Irritable Bowel Syndrome
Enrollment 20 participants
Start Date 2025-11-21
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-12-17